Current research toward optimizing dosing of first-line antituberculosis treatment

References

• van Crevel R, Alisjahbana B, de Lange WC, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis. 2002;6(6):497–502.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170–1177.
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546–2551.
   PubMed Web of Science ®Google Scholar
• Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685–1694.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Rustomjee R, Vahedi M, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232–3238.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–1473.
   PubMed Web of Science ®Google Scholar
• Jeremiah K, Denti P, Chigutsa E, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother. 2014;58(6):3468–3474.
   PubMed Web of Science ®Google Scholar
• Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother. 2015;59(1):38–45.
   PubMed Web of Science ®Google Scholar
• Denti P, Jeremiah K, Chigutsa E, et al. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary tb patients in tanzania. PLoS One. 2015;10(10):e0141002.
   PubMed Web of Science ®Google Scholar
• Chirehwa MT, Rustomjee R, Mthiyane T, et al. Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother. 2015;60(1):487–494.
   PubMed Web of Science ®Google Scholar
• Rockwood N, Meintjes G, Chirehwa M, et al. HIV-1 Coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in south african tuberculosis outpatients. Antimicrob Agents Chemother. 2016;60(10):6050–6059.
   PubMed Web of Science ®Google Scholar
• Chirehwa MT, McIlleron HM, Wiesner L, et al. Population pharmacokinetics of 1st-line antituberculosis drugs administered under three treatment strategies in TB/HIV patients from West Africa [abstract P_23]. 9th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2016 Oct 24; Liverpool (United Kingdom).
   Google Scholar
• Chirehwa MT, McIlleron H, Rustomjee R, et al. Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(8):e00490–17.
   PubMed Web of Science ®Google Scholar
• Chirehwa M, McIlleron H, Wiesner L, et al. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. J Antimicrob Chemother. 2018. [Epub ahead of print]. DOI:10.1093/jac/dky378.
   PubMed Web of Science ®Google Scholar
• Prahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother. 2014;69(10):2841–2847.
   PubMed Web of Science ®Google Scholar
• Mah A, Kharrat H, Ahmed R, et al. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. Int J Tuberc Lung Dis. 2015;19(2):210–215.
   PubMed Web of Science ®Google Scholar
• Rockwood N, Pasipanodya JG, Denti P, et al. Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis. Clin Infect Dis. 2017;64(10):1350–1359.
   PubMed Web of Science ®Google Scholar
• Guiastrennec B, Ramachandran G, Karlsson MO, et al. Suboptimal antituberculosis drug concentrations and outcomes in small and HIV-coinfected children in India: recommendations for dose modifications. Clin Pharmacol Ther. 2017. DOI:10.1002/cpt.987.
   Web of Science ®Google Scholar
• Jindani A, Borgulya G, de Patiño IW, et al. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(6):832–838.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49.
   PubMed Web of Science ®Google Scholar
• Savic RM, Weiner M, MacKenzie WR, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017;102(2):321–331.
   PubMed Web of Science ®Google Scholar
• Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J Infect Dis. 2018;218(6):991–999.
   PubMed Web of Science ®Google Scholar
• Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. a randomized controlled trial. Am J Respir Crit Care Med. 2018;198(5):657–666.
   PubMed Web of Science ®Google Scholar
• Njie GJ, Morris SB, Woodruff RY, et al. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018;55(2):244–252.
   PubMed Web of Science ®Google Scholar
• Achmad TH, van der Ven AJ, Borm G, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35.
   PubMed Web of Science ®Google Scholar
• Shenje J, Ifeoma Adimora-Nweke F, Ross IL, et al. Poor penetration of antibiotics into pericardium in pericardial tuberculosis. EBioMedicine. 2015;2(11):1640–1649.
   PubMed Web of Science ®Google Scholar
• Savic RM, Ruslami R, Hibma JE, et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015;98(6):622–629.
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Akkerman OW, Sturkenboom MG, et al. Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. Int J Mycobacteriol. 2016;5(Suppl 1):S44–S45.
   PubMedGoogle Scholar
• Lange C, Alghamdi WA, Al-Shaer MH, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. J Intern Med. 2018 May 28. [Epub ahead of print]. DOI:10.1111/joim.12780.
   Web of Science ®Google Scholar
• Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(9):2305–2313.
   PubMed Web of Science ®Google Scholar
• Pillai G, Fourie PB, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis. 1999;3(11):S309–16.
   PubMed Web of Science ®Google Scholar
• Hao LH, Guo SC, Liu CC, et al. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations. Int J Tuberc Lung Dis. 2014;18(12):1505–1512.
   PubMed Web of Science ®Google Scholar
• Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, et al. Low anti-tuberculosis drug concentrations in HIV-Tuberculosis co-infected adults with low body weight. [Abstract 39]. 11th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2018 Oct 23; The Hague (Netherlands).
   Google Scholar
• McIlleron H, Wash P, Burger A, et al. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis. 2002;6(4):356–361.
   PubMed Web of Science ®Google Scholar
• Milán-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis. 2010;14(11):1454–1460.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Hundt H, Smythe W, et al. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. Int J Tuberc Lung Dis. 2016;20(7):915–919.
   PubMed Web of Science ®Google Scholar
• Court R, Chirehwa MT, Wiesner L, et al. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis. 2018 May 1;22(5):537–543.
   PubMed Web of Science ®Google Scholar
• Survey of the quality of antituberculosis medicines circulating in selected newly independent states of the former Soviet Union. Geneva: World Health Organization; 2011. (WHO/EMP/QSM/2011.2). Accessed 2018 Aug 28. Available from: https://extranet.who.int/prequal/sites/default/files/documents/TBQuality-Survey_Nov2011_1.pdf
   Google Scholar
• Singh S, Mohan B. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. Int J Tuberc Lung Dis. 2003;7(3):298–303.
   PubMed Web of Science ®Google Scholar
• Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization; 2010. (WHO/HTM/TB/2009.420). Accessed 2018 Sept 14. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/
   Google Scholar
• Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization; 2014. (WHO/HTM/TB/2014.03). Accessed 2018 Aug 29. Available from: http://www.who.int/tb/publications/childtb_guidelines/en/
   Google Scholar
• Denti P, Gonzalez-Martinez C, Winckler J, et al. Pharmacokinetics of rifampicin in African children: evaluation of the new WHO dosing guidelines [abstract OA-155–13]. 48th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease; 2017 Oct 11–14; Guadalajara (Mexico). Int J Tuberc Lung Dis. 2017;21(11):S203.
   Google Scholar
• Horita Y, Alsultan A, Kwara A, et al. evaluation of the adequacy of who revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother. 2018;62(9):e00008–18.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Chabala C, Wiesner L, et al. Rifampicin and pyrazinamide exposures in children with DS-TB on WHO-recommended FDCs in the SHINE trial [abstract oa22–340–27]. 49th UnionWorld Conference on Lung Health; 2018 Oct 24–27; The Hague (Netherlands). Int J Tuberc Lung Dis. 2018;22(11):S441.
   Google Scholar
• Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941–2952.
   PubMed Web of Science ®Google Scholar
• Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14(7):563–571.
   PubMed Web of Science ®Google Scholar
• Griesel R, Stewart A, van der Plas H, et al. Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis. AIDS Res Ther. 2018;15(1):5.
   PubMedGoogle Scholar
• Javaid A, Ahmad N, Afridi AK, et al. validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: a retrospective single-center study. Am J Trop Med Hyg. 2018;98(6):1629–1636.
   PubMed Web of Science ®Google Scholar
• Chirehwa MT, Court R, De Kock M, et al. Moxifloxacin population pharmacokinetics and exposure/MIC target attainment in patients on treatment for MDR-TB [Abstract 21]. 11th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2018 Oct 23; The Hague (Netherlands).
   Google Scholar
• Wasserman S, Denti P, Brust J, et al. Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis [Abstract 9]. 11th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2018 Oct 23; The Hague (Netherlands).
   Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Zvada SP, Denti P, Donald PR, et al. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. J Antimicrob Chemother. 2014;69(5):1339–1349.
   PubMed Web of Science ®Google Scholar
• Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother. 2015;70(4):1115–1123.
   PubMed Web of Science ®Google Scholar
• Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised who-recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60(4):2171–2179.
   PubMed Web of Science ®Google Scholar
• Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization; 2010. (WHO/HTM/TB/2010.13). Accessed 2018 Aug 30. Available from: http://apps.who.int/iris/bitstream/handle/10665/44444/9789241500449_eng.pdf?sequence=1
   Google Scholar
• McIlleron H, Chirehwa M, Chabala C, et al. Rifampicin, isoniazid and pyrazinamide exposures in children with DS-TB on WHO-recommended FDCs in the SHINE trial [Abstract 6]. 11th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2018 23 Oct; The Hague (Netherlands).
   Google Scholar
• Thee S, Seifart HI, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother. 2011;55(10):4594–4600.
   PubMed Web of Science ®Google Scholar
• Thee S, Garcia-Prats AJ, Draper HR, et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis. 2015;60(4):549–556.
   PubMed Web of Science ®Google Scholar
• Garcia-Prats AJ, Draper HR, Thee S, et al. Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents Chemother. 2015;59(10):6073–6079.
   PubMed Web of Science ®Google Scholar
• Denti P, Garcia-Prats AJ, Draper HR, et al. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2018;62(2):e01521–17.
   PubMed Web of Science ®Google Scholar
• Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis. 2004;38:280–283.
   PubMed Web of Science ®Google Scholar
• Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004;48:4473–4475.
   PubMed Web of Science ®Google Scholar
• Pinheiro VG, Ramos LM, Monteiro HS, et al. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis. 2006;10:374–379.
   PubMedGoogle Scholar
• Facanha MC, Gondim AM, Pinheiro VG, et al. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. Braz J Infect Dis. 2009;13:210–217.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Watkins ML, Folb PI, et al. Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87(6):557–564.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Manley I, Scott B, et al. A pilot study of immune activation and rifampin absorption in hiv-infected patients without tuberculosis infection: a short report. Tuberc Res Treat. 2017;2017:2140974.
   PubMedGoogle Scholar
• Vinnard C, Ravimohan S, Tamuhla N, et al. Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. J Antimicrob Chemother. 2017;72(7):2020–2027.
   PubMed Web of Science ®Google Scholar
• Alghamdi WA, Al-Shaer MH, Peloquin CA. Protein binding of first-line antituberculosis drugs. Antimicrob Agents Chemother. 2018;62(7):e00641–18.
   PubMed Web of Science ®Google Scholar
• Denti P, Martinson N, Cohn S, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–1241.
   PubMed Web of Science ®Google Scholar
• Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155(5):1717–1722.
   PubMed Web of Science ®Google Scholar
• Verhagen LM, Coenen MJ, López D, et al. Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. Pharmacogenomics. 2014;15(3):285–296.
   PubMed Web of Science ®Google Scholar
• Hemanth Kumar AK, Ramesh K, Kannan T, et al. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. Indian J Med Res. 2017;145(1):118–123.
   PubMed Web of Science ®Google Scholar
• Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–1101.
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008 Feb;12(2):139–145.
   PubMed Web of Science ®Google Scholar
• Cordes H, Thiel C, Aschmann HE, et al. A physiologically based pharmacokinetic model of isoniazid and its application in individualizing tuberculosis chemotherapy. Antimicrob Agents Chemother. 2016;60(10):6134–6145.
   PubMed Web of Science ®Google Scholar
• Zuur MA, Pasipanodya JG, van Soolingen D, et al. Intermediate susceptibility dose-dependent breakpoints for high dose rifampicin, isoniazid and pyrazinamide treatment in multidrug-resistant tuberculosis programmes. Clin Infect Dis. 2018 Apr 24. DOI:10.1093/cid/ciy346.
   PubMed Web of Science ®Google Scholar
• Shi J, Xie M, Wang J, et al. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics. 2015;16(18):2083–2097.
   PubMed Web of Science ®Google Scholar
• Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018. (WHO/CDS/TB/2018.6). Accessed 2018 Sept 2. Available from: http://apps.who.int/iris/bitstream/handle/10665/260440/WHO-CDS-TB-2018.6-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Ho HT, Wang TH, Hsiong CH, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2013;23(4):200–207.
   PubMed Web of Science ®Google Scholar
• McCallum AD, Schipani A, Owen A, et al. Genetic determinants of the pharmacokinetic variability of isoniazid and rifampicin in Malawian adults with pulmonary tuberculosis [abstract OA-422–05]. 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease; 2015 Dec 2–6; Cape Town (South Africa). Int J Tuberc Lung Dis. 2015;19(12):S293.
   Google Scholar
• Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54(10):4192–4200.
   PubMed Web of Science ®Google Scholar
• Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122–4127.
   PubMed Web of Science ®Google Scholar
• Gengiah TN, Botha JH, Soowamber D, et al. Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries. 2014;8(8):987–993.
   PubMed Web of Science ®Google Scholar
• Hennig S, Naiker S, Reddy T, et al. Effect of SLCO1B1 polymorphisms on rifabutin pharmacokinetics in African HIV-infected patients with tuberculosis. Antimicrob Agents Chemother. 2015;60(1):617–620.
   PubMed Web of Science ®Google Scholar
• Sloan DJ, McCallum AD, Schipani A, et al. Genetic ##. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00210–17.
   PubMedGoogle Scholar
• Dompreh A, Tang X, Zhou J, et al. Effect of genetic variation of nat2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in ghanaian children with tuberculosis. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02099–17.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fukami T, Kobayashi Y, et al. A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. Drug Metab Dispos. 2012;40:1183–1190.
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother. 2007;51(8):2861–2866.
   PubMed Web of Science ®Google Scholar
• Naidoo A, Ramsuran V, Chirehwa M, et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics. 2018;19(1):17–29.
   PubMed Web of Science ®Google Scholar
• Weiner M, Gelfond J, Johnson-Pais TL, et al. Elevated plasma moxifloxacin concentrations and SLCO1B1 g.-11187G>A polymorphism in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2018;62(5):e01802–17.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196(Suppl 1):S63–75.
   PubMed Web of Science ®Google Scholar
• Maartens G, Boffito M, Flexner CW. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. Curr Opin HIV AIDS. 2017;12(4):355–358.
   PubMed Web of Science ®Google Scholar
• Naiker S, Connolly C, Wiesner L, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014;15:61.
   PubMed Web of Science ®Google Scholar
• Hennig S, Svensson EM, Niebecker R, et al. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. J Antimicrob Chemother. 2016;71(5):1330–1340.
   PubMed Web of Science ®Google Scholar
• Lan NT, Thu NT, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9(1):e84866.
   PubMed Web of Science ®Google Scholar
• Moultrie H, McIlleron H, Sawry S, et al. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. J Antimicrob Chemother. 2015;70(2):543–549.
   PubMed Web of Science ®Google Scholar
• Bhatt NB, Barau C, Amin A, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother. 2014;58(6):3182–3190.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Aweeka F, Park JG, et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780–2787.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406–6412.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015;70(4):1106–1114.
   PubMed Web of Science ®Google Scholar
• Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49(2):212–217.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother. 2017;72(12):3398–3405.
   PubMed Web of Science ®Google Scholar
• Tanneau L, Svensson EM, Rossenu S, et al. Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect [abstract 8634; www.page-meeting.org/?abstract=8634]. PAGE 27; 2018 May 29-June 1; Montreux (Switzerland): PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. ISSN 1871–6032.
   Google Scholar
• TB Alliance. Cycloserine. Tuberculosis. 2008;88:100–101.
   PubMedGoogle Scholar
• Court R, Chirehwa MT, Wiesner L, et al. Bioavailability of pyrazinamide, moxifloxacin, isoniazid, ethambutol, and terizidone when tablets are crushed in the treatment of multidrug-resistant tuberculosis [Abstract 25]. 11th International Workshop on Clinical Pharmacology of Tuberculosis Drugs; 2018 Oct 23; The Hague (Netherlands).
   Google Scholar
• Winckler JL, Schaaf SH, Draper HR, et al. The pharmacokinetics of high dose Isoniazid for the prevention or treatment of drug-resistant tuberculosis in HIV-infected and -uninfected children [abstract ep04–128–26]. 49th UnionWorld Conference on Lung Health; 2018 Oct 24–27; The Hague (Netherlands). Int J Tuberc Lung Dis. 2018;22(11):S314.
   Google Scholar
• Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001–1007.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642–1651.
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587.
   PubMed Web of Science ®Google Scholar
• Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030.
   PubMed Web of Science ®Google Scholar
• Naidoo A, Chirehwa M, McIlleron H, et al. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother. 2017;72(5):1441–1449.
   PubMed Web of Science ®Google Scholar
• Zhang C, Denti P, Decloedt EH, et al. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. Br J Clin Pharmacol. 2013;76(5):741–751.
   PubMed Web of Science ®Google Scholar
• Nix DE, Adam RD, Auclair B, et al. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb). 2004;84(6):365–373.
   PubMed Web of Science ®Google Scholar
• Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother. 2010;54(8):3390–3394.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Sirturo product information. Product information. EMEA/H/C/002614 -R/0024; [ updated 05/03/2018; cited 2018 Aug 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002614/WC500163209.pdf
   Google Scholar
• European Medicines Agency. Deltyba product information. Product information. EMEA/H/C/002552 -IAIN/0031. 11/06/2018; [ cited 2018 Aug 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf
   Google Scholar
• Weiner M, Savic RM, Kenzie WR, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3(2):132–145.
   PubMedGoogle Scholar
• Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther. 1991;50(5 Pt 1):498–502.
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet. 2001;40(Suppl 1):57–62.
   PubMedGoogle Scholar
• Rao KV, Kailasam S, Menon NK, et al. Inactivation of isoniazid by condensation in a syrup preparation. Bull World Health Organ. 1971;45(5):625–632.
   PubMed Web of Science ®Google Scholar
• Giardiello M, Liptrott NJ, McDonald TO, et al. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nat Commun. 2016;7:13184.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018. DOI:10.1111/bcp.13696.
   PubMed Web of Science ®Google Scholar
• Harausz EP, Leigh J, Garcia-Prats AJ, et al. Stability of second-line tuberculosis medications mixed with milk or yogurt. Clin Infect Dis. 2017;65(4):704–705.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Yngman G, Denti P, et al. Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy. Clin Pharmacokinet. 2018;57(5):591–599.
   PubMed Web of Science ®Google Scholar